The association of hepatitis C virus infection and post-liver transplant diabetes: Data from 17 000 HCV-infected transplant recipients

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 2, 2015, Pages 209-217

  Younossi, Z ^a,b   Stepanova, M ^a,b   Saab, S ^c   Trimble, G ^a,b   Mishra, A ^a,b   Henry, L ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OBESITY; OBSERVATIONAL STUDY; RISK ASSESSMENT; RISK FACTOR; ADVERSE EFFECTS; COMPLICATION; HEPACIVIRUS; INCIDENCE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TIME; UNITED STATES;

DIABETES MELLITUS; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS C; HUMANS; INCIDENCE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS; TRANSPLANT RECIPIENTS; UNITED STATES;

EID: 84918510014     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13027     Document Type: Article

References (35)

1. Naing C, Mak JW, Ahmed SI, Maung M,. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol 2012; 18: 1642-51.
2. White DL, Ratziu V, El-Serag HB,. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 831-44.
3. Negro F, Alaei M,. Hepatitis C virus and type 2 diabetes. World J Gastroenterol 2009; 15: 1537-47.
4. Zheng Z, Zhang C, Yan J, et al,. Diabetes mellitus is associated with hepatocellular carcinoma: a retrospective case-control study in hepatitis endemic area. PLoS ONE 2013; 8: e84776.
5. Younossi ZM, Kanwal F, Saab S, et al,. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014; 39: 518-31.
6. Mason AL, Lau JY, Hoang N, et al,. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-33.
7. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL,. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 2000; 133: 592-9.
8. Mehta SH, Brancati FL, Strathdee SA, et al,. Hepatitis C virus infection and incident type 2 diabetes. Hepatology 2003; 38: 50-6.
9. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J,. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996; 19: 998-1000.
10. Kiran Z, Zuberi BF, Anis D, Qadeer R, Hassan K, Afsar S,. Insulin resistance in non-diabetic patients of chronic Hepatitis C. Pak J Med Sci 2013; 29: 201-4.
11. Memon MS, Arain ZI, Naz F, Zaki M, Kumar S, Burney AA,. Prevalence of type 2 diabetes mellitus in hepatitis C virus infected population: a Southeast Asian study. J Diabetes Res 2013; 2013: 539361.
12. Stepanova M, Lam B, Younossi Y, Srishord MK, Younossi ZM,. Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. J Viral Hepat 2012; 19: 341-5.
13. Ruhl CE, Menke A, Cowie CC, Everhart JE,. The relationship of hepatitis C virus infection with diabetes in the United States population. Hepatology 2014; 60: 1139-49.
14. Kawaguchi Y, Mizuta T,. Interaction between hepatitis C virus and metabolic factors. World J Gastroenterol 2014; 20: 2888-901.
15. Kawaguchi T, Yoshida T, Harada M, et al,. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 2004; 165: 1499-508.
16. Strassburg CP, Obermayer-Straub P, Manns MP,. Autoimmunity in hepatitis C and D virus infection. J Viral Hepat 1996; 3: 49-59.
17. Yadav AD, Chang YH, Aqel BA, et al,. New onset diabetes mellitus in living donor versus deceased donor liver transplant recipients: analysis of the UNOS/OPTN database. J Transplant 2013; 2013: 269096.
18. Saliba F, Lakehal M, Pageaux GP, et al,.; Diapason Study Group. Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection: an observational multicenter study. Liver Transpl 2007; 13: 136-44.
19. Wu Y, Ahmed A, Kamal A,. Donor diabetes mellitus is an independent risk factor for graft loss in HCV positive but not HCV negative liver transplant recipients. Dig Dis Sci 2013; 58: 574-8.
20. Veldt BJ, Duarte-Rojo A, Thompson AJ, et al,. Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. Am J Transplant 2012; 12: 737-44.
21. Gane EJ,. Diabetes mellitus following liver transplantation in patients with hepatitis C virus: risks and consequences. Am J Transplant 2012; 12: 531-8.
22. Gelley F, Zadori G, Firneisz G, et al,. Relationship between hepatitis C virus recurrence and de novo diabetes after liver transplantation: the Hungarian experience. Transpl Proc 2011; 43: 1281-2.
23. Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S,. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 2010; 89: 1134-40.
24. Chen T, Jia H, Li J, Chen X, Zhou H, Tian H,. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transpl Int 2009; 22: 408-15.
25. Sanchez-Perez B, Aranda Narvaez JM, Santoyo Santoyo J, et al,. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients. Transpl Proc 2008; 40: 2994-6.
26. The Scientific Registry of Transplant Recipients (SRTR). The Standard Analysis File dictionary. Available at: http://www.srtr.org/data-request/datadictionary/1309/files/fmt.htm#fmt101 (accessed 18 April 2014).
27. Wiesner R, Edwards E, Freeman R, et al,. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-6.
28. Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM,. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol 2010; 8: 1017-29.
29. Ruhl CE, Menke A, Cowie CC, Everhart JE,. Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology 2014; 60: 1139-49.
30. Zarrinpar A, Loomba R,. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 36: 909-21.
31. Vernon G, Baranova A, Younossi ZM,. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
32. Stepanova M, Wai H, Saab S, Mishra A, Venkatesan C, Younossi ZM,. The portrait of an adult liver transplant recipient in the United States from 1987 to 2013. JAMA Intern Med 2014; 174: 1407-9.
33. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
34. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
35. Afdhal N, Zeuzem S, Kwo P, et al,. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.